We provide the latest news
from the world of economics and finance
(RTTNews) - Enlivex Therapeutics Ltd. (ENLV), Monday announced a positive interim data from a Phase I/II clinical trial of Allocetra in patients with severe knee osteoarthritis patients indicated for knee replacement surgery.
The company said it tried a single Allocetra injection to the knee as a potential last resort alternative for pain resolution and knee functionality in lieu of knee-replacement surgery.
A total of nine patients have been enrolled and treated with a single Allocetra injection to the knee and evaluated for at least three months following treatment.
At the three-month follow up, out of the nine patients enrolled, eight of them reported an improvement in their knee pain compared to their baseline pain prior to treatment, while 33 of the patients reported complete pain relief.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.